High Growth Tech Stocks in Hong Kong for October 2024

In This Article:

As global markets navigate geopolitical tensions and economic shifts, Hong Kong's tech sector has shown resilience, with the Hang Seng Index climbing 10.2% amid optimism surrounding Beijing's supportive measures. In this dynamic environment, identifying high-growth tech stocks requires careful consideration of innovation potential and adaptability to market changes, making them attractive prospects for those looking to capitalize on technological advancements in a rapidly evolving landscape.

Top 10 High Growth Tech Companies In Hong Kong

Name

Revenue Growth

Earnings Growth

Growth Rating

Wasion Holdings

22.37%

25.47%

★★★★★☆

MedSci Healthcare Holdings

48.74%

48.78%

★★★★★☆

Inspur Digital Enterprise Technology

25.31%

39.04%

★★★★★☆

RemeGen

26.30%

52.19%

★★★★★☆

Innovent Biologics

21.80%

59.60%

★★★★★☆

Akeso

33.30%

53.00%

★★★★★★

Cowell e Holdings

31.68%

35.44%

★★★★★★

Biocytogen Pharmaceuticals (Beijing)

21.53%

109.17%

★★★★★☆

Beijing Airdoc Technology

37.47%

93.35%

★★★★★☆

Sichuan Kelun-Biotech Biopharmaceutical

24.70%

8.53%

★★★★★☆

Click here to see the full list of 43 stocks from our SEHK High Growth Tech and AI Stocks screener.

Let's explore several standout options from the results in the screener.

Innovent Biologics

Simply Wall St Growth Rating: ★★★★★☆

Overview: Innovent Biologics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibodies and other drug assets for oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases in China with a market cap of HK$79.68 billion.

Operations: The company generates revenue primarily from its biotechnology segment, amounting to CN¥7.46 billion. It focuses on developing and commercializing drug assets in various therapeutic areas within China.

Innovent Biologics, Inc. has demonstrated a robust commitment to innovation, particularly through its strategic collaborations and R&D initiatives. Recently, the company secured exclusive commercialization rights for limertinib in China, anticipating significant revenue from this lung cancer treatment given its promising clinical outcomes. Financially, Innovent reported a sharp 59.6% forecasted annual earnings growth and an impressive expected revenue increase of 21.8% per year—outpacing the broader Hong Kong market significantly. These figures underscore its potential in transforming patient care with advanced therapies while scaling its market presence aggressively.